Cargando…

Eldecalcitol, an active vitamin D analog, effectively prevents cyclophosphamide-induced osteoporosis in rats

Cyclophosphamide (CTX) as an alkylating agent is used for treating a range of tumor types and allergic diseases. However, high-dose application may induce rapid bone loss and increase the risk of osteoporotic fractures. Eldecalcitol (ED-71), a clinically approved active vitamin D analog, has been ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Gao, Yuan, Liu, Hongrui, Feng, Wei, Li, Xiaoyan, Guo, Jie, Li, Minqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676093/ https://www.ncbi.nlm.nih.gov/pubmed/31410111 http://dx.doi.org/10.3892/etm.2019.7759

Ejemplares similares

Inhibition of vitamin D analog eldecalcitol on hepatoma in vitro and in vivo
por: Ye, Limin, et al.
Publicado: (2020)

Eldecalcitol prevented OVX-induced osteoporosis through inhibiting BMSCs senescence by regulating the SIRT1-Nrf2 signal
por: Kou, Yuying, et al.
Publicado: (2023)

Eldecalcitol for the treatment of osteoporosis
por: Noguchi, Yuko, et al.
Publicado: (2013)

Eldecalcitol effects on osteoblastic differentiation and function in the presence or absence of osteoclastic bone resorption
por: Bu, Jie, et al.
Publicado: (2019)

Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials
por: Xu, Zhixing, et al.
Publicado: (2016)

Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials [Corrigendum]
Publicado: (2016)

Eldecalcitol effectively prevents alveolar bone loss by partially improving Th17/Treg cell balance in diabetes-associated periodontitis
por: Gao, Ruihan, et al.
Publicado: (2023)

The Synergistic Effect of Zuogui Pill and Eldecalcitol on Improving Bone Mass and Osteogenesis in Type 2 Diabetic Osteoporosis
por: Shi, Tuo, et al.
Publicado: (2023)

Comparison of the Effects of Native Vitamin D and Eldecalcitol on Muscular Strength and Dynamic Balance in Patients with Postmenopausal Osteoporosis
por: Miyakoshi, Naohisa, et al.
Publicado: (2020)

Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis
por: Sakai, A., et al.
Publicado: (2015)

Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis
por: Cui, Lijia, et al.
Publicado: (2022)

Erratum to: Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis
por: Sakai, A., et al.
Publicado: (2015)

Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis
por: Ono, Yuichi, et al.
Publicado: (2018)

Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

Eldecalcitol, an Active Vitamin D(3) Derivative, Prevents Trabecular Bone Loss and Bone Fragility in Type I Diabetic Model Rats
por: Takeda, Satoshi, et al.
Publicado: (2017)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
por: Liu, Hongyan, et al.
Publicado: (2022)

Exendin-4 and eldecalcitol synergistically promote osteogenic differentiation of bone marrow mesenchymal stem cells through M2 macrophages polarization via PI3K/AKT pathway
por: Lu, Yupu, et al.
Publicado: (2022)

Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Effects of eldecalcitol on cortical bone response to mechanical loading in rats
por: Yamasaki, Yusuke, et al.
Publicado: (2015)

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2012)

Human hepatic metabolism of the anti-osteoporosis drug eldecalcitol involves sterol C4-methyl oxidase
por: Yasuda, Kaori, et al.
Publicado: (2015)

Correction to: The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Eldecalcitol Inhibits LPS-Induced NLRP3 Inflammasome-Dependent Pyroptosis in Human Gingival Fibroblasts by Activating the Nrf2/HO-1 Signaling Pathway
por: Huang, Cancan, et al.
Publicado: (2020)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Two-year effectiveness of zoledronic acid with or without eldecalcitol in Japanese patients with osteoporosis: A randomized prospective study
por: Mochizuki, Takeshi, et al.
Publicado: (2022)

ED-71 Prevents Glucocorticoid-Induced Osteoporosis by Regulating Osteoblast Differentiation via Notch and Wnt/β-Catenin Pathways
por: Rong, Xing, et al.
Publicado: (2022)

Immunoporosis: Role of immune system in the pathophysiology of different types of osteoporosis
por: Zhang, Weidong, et al.
Publicado: (2022)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility
por: Aihara, Seishi, et al.
Publicado: (2019)

Pharmacokinetic and Bioequivalence Study of Eldecalcitol Soft Capsules in Healthy Chinese Subjects
por: Li, Ting, et al.
Publicado: (2022)

Comparative effect of eldecalcitol and alfacalcidol on bone microstructure: A preliminary report of secondary analysis of a prospective trial
por: Ni, Xiaolin, et al.
Publicado: (2021)

Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice
por: Zhang, Haichao, et al.
Publicado: (2022)

Severe Hypocalcemia and Resulting Seizure Caused by Vitamin D Deficiency in an Older Patient Receiving Phenytoin: Eldecalcitol and Maxacalcitol Ointment as Potential Therapeutic Options for Hypocalcemia
por: Aihara, Seishi, et al.
Publicado: (2019)

Protective effect of gonadotropin-releasing hormone analog on the ovarian reserve in rats receiving cyclophosphamide treatment
por: Gui, Ting, et al.
Publicado: (2015)

The future of vitamin D analogs
por: Leyssens, Carlien, et al.
Publicado: (2014)

Effects of Vitamin D on Asprosin Immunoreactivity Against Cyclophosphamide-Induced Liver Injury in Rats
por: Turk, Ahmet, et al.
Publicado: (2023)

Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats
por: Yano, Tetsuo, et al.
Publicado: (2021)

Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates
por: Iwamoto, Jun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5revm79u80pe14hi4aq0fm6po5